September 28, 2019
ESMO 2019: Forbius displays target engagement in Phase 1 immuno-oncology clinical trial with AVID200, TGF-beta 1 & 3 Inhibitor
AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, the main oncogenic TGF-beta isoforms AVID200 demonstrated peripheral…